Everything below concerns RP-HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-26. Numbers and descriptions here follow the published literature rather than marketing material.
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
| Property | Value | Notes |
|---|---|---|
| 保存温度 | 2 至 8 摄氏度 | 避免冻结，部分制剂允许短期室温 |
| 粉末外观 | 白色至类白色固体 | 吸湿后易结块 |
| 纯度检测方法 | 反相高效液相色谱 | 紫外检测，常用 214 纳米 |
| 分子量确认方法 | 液相色谱串联质谱 | 偏差通常以 ppm 表示 |
| 常见降解产物 | 氧化与脱酰胺变体 | 源自甲硫氨酸与天冬酰胺残基 |
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
The definitive management is the surgical removal of the insulinoma. This may involve removing part of the pancreas, as well (Whipple procedure and distal pancreatectomy). Medications such as diazoxide and somatostatin can be used to block the release of insulin for patients who are not surgical candidates or who otherwise have inoperable tumours. Streptozotocin is used in islet cell carcinomas which produce excessive insulin. Combination chemotherapy is used, either doxorubicin and streptozotocin, or fluorouracil and streptozocin in patients where doxorubicin is contraindicated. In metastasizing tumours with intrahepatic growth, hepatic arterial occlusion or embolization can be used.
Coghill made Andrew J. Moyer available to work on penicillin with Heatley, while Florey left to see if he could arrange for a pharmaceutical company to manufacture penicillin. As a first step to increasing yield, Moyer replaced sucrose in the growth media with lactose. An even larger increase occurred when Moyer added corn steep liquor, a byproduct of the corn industry that the NRRL routinely tried in the hope of finding more uses for it. The effect on penicillin was dramatic; Heatley and Moyer found that it increased the yield tenfold. At the Yale New Haven Hospital in March 1942, Anne Sheafe Miller, the wife of Yale University's athletics director, Ogden D. Miller, was succumbing to a streptococcal septicaemia contracted after a miscarriage. Her doctor, John Bumstead, was also treating John Fulton for an infection at the time. He knew that Fulton knew Florey, and that Florey's children were staying with him. He went to Fulton to plead for some penicillin. Florey had returned to the UK, but Heatley was still in the United States, working with Merck. A phone call to Richards released 5.5 grams of penicillin earmarked for a clinical trial, which was despatched from Washington, D. C., by air. The effect was dramatic; within 48 hours her 41 °C (106 °F) fever had abated and she was eating again. Her blood culture count had dropped from 100 to 150 bacteria colonies per millilitre to just one. Bumstead suggested reducing the penicillin dose from 200 milligrams; Heatley warned him not to.
== Food chain versus food web == A food chain differs from a food web as a food chain follows a direct linear pathway of consumption and energy transfer. Natural interconnections between food chains make a food web, which are non-linear and depict interconnecting pathways of consumption and energy transfer.
Sources: en.wikipedia.org
According to the High Court in New Faith v Commissioner of Payroll Tax (Victoria) this will include all practices that would protect the “religious susceptibilities” of adherents to that faith. A third exception in section 351(2)(a) is that employers are exempt from federal law if the action is "not unlawful under any anti-discrimination law in force in the place where the action is taken". In Rumble v The Partnerships the Fair Work Commission held that a law firm consultant, Dr Rumble, could lawfully be dismissed for publicly criticising the Department of Defence for ignoring problems of sexual misconduct in the defence forces, because breach of the firm's media comment policy was a valid reason for dismissal – and this was accepted to be lawful. But Perram J also gave the opinion that if the dismissal had taken place in NSW, which does not protect political opinions, then section 351(2)(a) would have defeated the claim.
Verbena officinalis var. africana (R. Fern. & Verdc.) Munir (=V. officinalis ssp. africana R.Fern. & Verdc.) Verbena officinalis var. eremicola Munir Verbena officinalis var. gaudichaudii Briq. Verbena officinalis var. macrostachya (F. Muell.) Benth. (=V. macrostachya) Verbena officinalis var. monticola Munir Verbena officinalis var. officinalis L. (=V. domingensis) The Texas vervain (V. halei) is sometimes included in V. officinalis as a subspecies or variety. But despite the outward similarity, biogeography alone strongly suggests there is really no justification to include this North American native here, and DNA sequence data agrees. Instead, V. halei seems to be closely related to V. macdougalii, perhaps with some interbreeding with the V. menthifolia lineage which might explain its Common Vervain-like traits.
People with myasthenia gravis undergoing surgery with inhaled anesthetics (i.e., halothane, isoflurane, enflurane, and sevoflurane) may develop neuromuscular blockage and have an increased incidence of developing a life-threatening myasthenia crisis which must be treated by prolonged mechanical ventilation. In a study of 795 people with myasthenia gravis undergoing surgical removal of their thymus under general anesthesia, sugammadex, a neuromuscular-blocking drug (i.e., a drug that reverses neuromuscular blockade) significantly reduced the development of this crisis. Glucocorticoids: Glucocorticoids are anti-inflammatory agents that in initial studies were used at high dosages and found to worsen myasthenia gravis in 25-75% of cases. However, further studies found that glucocorticoids do have favorable effects on myasthenia gravis when taken long term. Two glucocorticoids, oral prednisone and prednisolone, are the first-line immunosuppressive treatment for myasthenia gravis. A review published in 2020 on 27 earlier publications found that myasthenia gravis was worsened by glucocorticoids in 33.3% of patients. These myasthenia gravis exacerbations seemed significantly greater for cortisone, intermediate for prednisone, and lowest for methylprednisolone. High dosages or alternate day dosages of prednisone were associated with exacerbation more frequently than low-dose treatments.
Sources: en.wikipedia.org
== History == DOM was the first psychedelic of the DOx series to be discovered. It was first synthesized by Alexander Shulgin at Dow Chemical Company in 1963, who had had his first psychedelic experience, with mescaline (3,4,5-trimethoxyphenethylamine), in 1960. Shulgin personally tried DOM on January 4, 1964 and discovered its psychedelic effects. 2,4,5-Trimethoxyamphetamine (TMA-2; "DOMeO") had been synthesized by Bruckner in 1933, but its psychedelic effects were not described until Shulgin tried the compound and reported its effects in the scientific literature in 1964. Prior to this, 3,4,5-trimethoxyamphetamine (TMA; α-methylmescaline) had been synthesized by Hey in 1947, being found by him to produce euphoria, and was described by Peretz and colleagues in 1955 as clearly producing psychedelic effects. Following his discovery of DOM, Shulgin developed DOET and found that at low doses it was a remarkable "psychic energizer" without producing psychedelic effects at these doses. Dow Chemical Company decided to move forward with clinical trials of DOET as a potential pharmaceutical drug for such purposes. Shulgin and Dow Chemical Company filed a patent for DOET in 1966, although it was not published until 1970. Dow Chemical Company tasked Solomon H. Snyder at Johns Hopkins University with clinically studying DOET. In April 1967, following the banning of LSD in California in 1966, DOM emerged as a street drug and legal LSD alternative with the name "STP" (allegedly short for "Serenity, Tranquility, and Peace") in the Haight-Ashbury district in San Francisco.
Accelerator mass spectrometry (AMS) is a form of mass spectrometry that accelerates ions to extraordinarily high kinetic energies before mass analysis. The special strength of AMS among the different methods of mass spectrometry is its ability to separate a rare isotope from an abundant neighboring mass ("abundance sensitivity", e.g. 14C from 12C). The method suppresses molecular isobars completely and in many cases can also separate atomic isobars (e.g. 14N from 14C). This makes possible the detection of naturally occurring, long-lived radio-isotopes such as 10Be, 36Cl, 26Al and 14C. (Their typical isotopic abundance ranges from 10−12 to 10−18.) AMS can outperform the competing technique of decay counting for all isotopes where the half-life is long enough. Other advantages of AMS include its short measuring time as well as its ability to detect atoms in extremely small samples.
== Pharmacology == Chlordiazepoxide acts on benzodiazepine allosteric sites that are part of the GABAA receptor/ion-channel complex and this results in an increased binding of the inhibitory neurotransmitter GABA to the GABAA receptor thereby producing inhibitory effects on the central nervous system and body similar to the effects of other benzodiazepines. Chlordiazepoxide is an anticonvulsant. Chlordiazepoxide is preferentially stored in some organs including the hearts of neonates. Absorption by any administered route and the risk of accumulation is significantly higher in neonates. The withdrawal of chlordiazepoxide during pregnancy and breast feeding is recommended, as chlordiazepoxide rapidly crosses the placenta and also is excreted in breast milk. Chlordiazepoxide also decreases prolactin release in rats. Benzodiazepines act via micromolar benzodiazepine binding sites as Ca2+ channel blockers and significantly inhibit depolarization-sensitive Calcium uptake in animal nerve terminal preparations. Chlordiazepoxide inhibits acetylcholine release in mouse hippocampal synaptosomes in vivo. This has been found by measuring sodium-dependent high affinity choline uptake in vitro after pretreatment of the mice in vivo with chlordiazepoxide. This may play a role in chlordiazepoxide's anticonvulsant properties.
Sources: en.wikipedia.org
冻融过程中冰晶形成与局部浓度升高会促使肽链发生界面吸附和聚集。聚集不仅降低有效含量，还会改变可见异物与不溶性微粒的计数结果。将溶液分装为单次使用的小体积等份可减少循环次数。
该方法依据疏水性差异分离主峰与相关杂质，对缺失序列、氧化产物和脱酰胺变体具有较好分辨能力。流动相中加入离子对试剂可改善峰形。紫外检测在肽键吸收区工作，灵敏度足以支持常规放行检验。
加速条件可以放大多数化学降解，但聚集与界面诱导的变化对容器、摇动和温度历史更敏感。某些固态转变在短时高温下不一定出现。因此实时稳定性数据仍不可替代，加速结果一般只作为趋势参考。
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.